Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer

The promise of poly(ADP-ribose) polymerase inhibitors (PARPis) in the management of epithelial ovarian cancer (EOC) is hampered by the limited clinical activity against BRCA wild-type or homologous recombination-proficient EOC. In order to decrease the resistance and increase the efficacy of PARPis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yan, Chen, Ping, Drisko, Jeanne A., Khabele, Dineo, Godwin, Andrew K., Chen, Qi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068513/
https://www.ncbi.nlm.nih.gov/pubmed/32218813
http://dx.doi.org/10.3892/ol.2020.11364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068513/
https://www.ncbi.nlm.nih.gov/pubmed/32218813
http://dx.doi.org/10.3892/ol.2020.11364

Ejemplares similares